STAAR Surgical Company (NASDAQ:STAA) Receives Average Recommendation of "Hold" from Brokerages

Key Points

• Analysts show an average recommendation of Hold on STAAR Surgical from 11 brokerages (2 sell, 7 hold, 2 buy) with a mean 12‑month price target of $19.93.
• Significant insider and institutional accumulation: Broadwood Partners bought 316,017 shares and now holds 16.12M shares (a 2% increase), insiders purchased 670,213 shares over the last 90 days, and institutional ownership is 96.7% with several firms materially adding stakes.
• Recent results missed expectations—quarterly EPS was -$0.37 vs. $0.14 expected and revenue was $57.8M vs. $75.5M expected—leaving the company with negative net margin and ROE despite 18% revenue growth year‑over‑year.

STAAR Surgical Company (NASDAQ:STAA - Get Free Report) has received an average recommendation of "Hold" from the eleven brokerages that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $19.9286.

Several research analysts have issued reports on the company. Stifel Nicolaus dropped their target price on STAAR Surgical from $19.00 to $18.00 and set a "hold" rating on the stock in a research report on Wednesday, March 4th. Wedbush raised their target price on STAAR Surgical from $21.00 to $26.00 and gave the stock a "neutral" rating in a research report on Thursday, April 9th. Wells Fargo & Company dropped their target price on STAAR Surgical from $30.75 to $16.00 and set an "equal weight" rating on the stock in a research report on Thursday, March 5th. Canaccord Genuity Group raised STAAR Surgical from a "hold" rating to a "buy" rating and raised their target price for the stock from $22.00 to $27.00 in a research report on Thursday, April 9th. Finally, BTIG Research reissued a "neutral" rating on shares of STAAR Surgical in a research report on Tuesday, January 6th.

Insider Activity at STAAR Surgical

In related news, Director Broadwood Partners, L.P. acquired 316,017 shares of the firm's stock in a transaction dated Friday, March 13th. The shares were purchased at an average price of $18.61 per share, with a total value of $5,881,076.37. Following the completion of the purchase, the director directly owned 16,123,842 shares of the company's stock, valued at $300,064,699.62. This represents a 2.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders bought a total of 670,213 shares of company stock valued at $12,266,249 over the last 90 days. 0.59% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Broadwood Capital Inc. raised its stake in shares of STAAR Surgical by 11.1% in the fourth quarter. Broadwood Capital Inc. now owns 15,019,491 shares of the medical instruments supplier's stock worth $346,800,000 after buying an additional 1,500,000 shares during the period. Soleus Capital Management L.P. raised its stake in shares of STAAR Surgical by 16.5% in the second quarter. Soleus Capital Management L.P. now owns 2,984,733 shares of the medical instruments supplier's stock worth $50,084,000 after buying an additional 421,840 shares during the period. Yunqi Capital Ltd raised its stake in shares of STAAR Surgical by 0.3% in the fourth quarter. Yunqi Capital Ltd now owns 2,507,130 shares of the medical instruments supplier's stock worth $57,890,000 after buying an additional 7,069 shares during the period. Magnetar Financial LLC raised its stake in shares of STAAR Surgical by 105.3% in the fourth quarter. Magnetar Financial LLC now owns 2,472,390 shares of the medical instruments supplier's stock worth $57,087,000 after buying an additional 1,268,019 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in shares of STAAR Surgical by 112.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,076,743 shares of the medical instruments supplier's stock worth $47,952,000 after buying an additional 1,100,484 shares during the period. Institutional investors own 96.70% of the company's stock.

STAAR Surgical Stock Performance

Shares of NASDAQ:STAA opened at $25.67 on Friday. The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of -15.75 and a beta of 1.04. The stock's 50-day simple moving average is $20.28 and its two-hundred day simple moving average is $22.48. STAAR Surgical has a 52-week low of $15.59 and a 52-week high of $30.81.

STAAR Surgical (NASDAQ:STAA - Get Free Report) last announced its earnings results on Tuesday, March 3rd. The medical instruments supplier reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.14 by ($0.51). The firm had revenue of $57.80 million during the quarter, compared to analysts' expectations of $75.54 million. STAAR Surgical had a negative return on equity of 10.03% and a negative net margin of 33.60%.STAAR Surgical's revenue for the quarter was up 18.0% compared to the same quarter last year. As a group, equities analysts forecast that STAAR Surgical will post -0.03 earnings per share for the current fiscal year.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.